And the next question is whether browbeating the FDA in this way is likely to put its back up or cause it to retreat into bureaucratic inertia. Inertia on Copaxone is all Teva needs.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.